JP7638252B2 - 細胞トランスフェクションのエレクトロポレーション装置及び方法 - Google Patents
細胞トランスフェクションのエレクトロポレーション装置及び方法 Download PDFInfo
- Publication number
- JP7638252B2 JP7638252B2 JP2022187279A JP2022187279A JP7638252B2 JP 7638252 B2 JP7638252 B2 JP 7638252B2 JP 2022187279 A JP2022187279 A JP 2022187279A JP 2022187279 A JP2022187279 A JP 2022187279A JP 7638252 B2 JP7638252 B2 JP 7638252B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- electroporation
- chamber
- phosphate
- electrode
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004520 electroporation Methods 0.000 title claims description 370
- 238000000034 method Methods 0.000 title description 97
- 238000001890 transfection Methods 0.000 title description 55
- 239000000872 buffer Substances 0.000 claims description 35
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 8
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 8
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 8
- 239000001506 calcium phosphate Substances 0.000 claims description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 7
- 239000002953 phosphate buffered saline Substances 0.000 claims description 7
- 239000001488 sodium phosphate Substances 0.000 claims description 7
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 235000019800 disodium phosphate Nutrition 0.000 claims description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 4
- 229910000151 chromium(III) phosphate Inorganic materials 0.000 claims description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 4
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 4
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 4
- 239000004137 magnesium phosphate Substances 0.000 claims description 4
- 229910001507 metal halide Inorganic materials 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019798 tripotassium phosphate Nutrition 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000007836 KH2PO4 Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229910000150 monocalcium phosphate Inorganic materials 0.000 claims description 3
- 235000019785 monomagnesium phosphate Nutrition 0.000 claims description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 3
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims description 2
- IKZBVTPSNGOVRJ-UHFFFAOYSA-K chromium(iii) phosphate Chemical compound [Cr+3].[O-]P([O-])([O-])=O IKZBVTPSNGOVRJ-UHFFFAOYSA-K 0.000 claims description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 claims description 2
- 235000019791 dimagnesium phosphate Nutrition 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 claims description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 claims description 2
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 claims description 2
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 claims description 2
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 claims description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 2
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 claims description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 2
- 229910000401 monomagnesium phosphate Inorganic materials 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 506
- 239000000463 material Substances 0.000 description 65
- 230000007246 mechanism Effects 0.000 description 54
- 230000005684 electric field Effects 0.000 description 45
- 239000012530 fluid Substances 0.000 description 40
- 238000002474 experimental method Methods 0.000 description 39
- 239000000243 solution Substances 0.000 description 36
- 210000001744 T-lymphocyte Anatomy 0.000 description 33
- 230000037361 pathway Effects 0.000 description 32
- 108020004999 messenger RNA Proteins 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 25
- 239000002609 medium Substances 0.000 description 23
- 210000000822 natural killer cell Anatomy 0.000 description 20
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 20
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 19
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 19
- 238000010586 diagram Methods 0.000 description 19
- 239000005090 green fluorescent protein Substances 0.000 description 19
- 239000004205 dimethyl polysiloxane Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 230000035899 viability Effects 0.000 description 17
- 238000004891 communication Methods 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- -1 polydimethylsiloxane Polymers 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000011148 porous material Substances 0.000 description 11
- 229920001212 Poly(beta amino esters) Polymers 0.000 description 10
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 10
- 239000010703 silicon Substances 0.000 description 10
- 229910052710 silicon Inorganic materials 0.000 description 10
- 230000003833 cell viability Effects 0.000 description 9
- 210000004962 mammalian cell Anatomy 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 239000002105 nanoparticle Substances 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
- 230000037452 priming Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108010020346 Polyglutamic Acid Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 229920002643 polyglutamic acid Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 150000002016 disaccharides Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- 238000000206 photolithography Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004642 Polyimide Substances 0.000 description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001721 polyimide Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 229920000144 PEDOT:PSS Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002041 carbon nanotube Substances 0.000 description 2
- 229910021393 carbon nanotube Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000005459 micromachining Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000011094 buffer selection Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003486 chemical etching Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001312 dry etching Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229910052735 hafnium Inorganic materials 0.000 description 1
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 238000001020 plasma etching Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 229910021481 rutherfordium Inorganic materials 0.000 description 1
- YGPLJIIQQIDVFJ-UHFFFAOYSA-N rutherfordium atom Chemical compound [Rf] YGPLJIIQQIDVFJ-UHFFFAOYSA-N 0.000 description 1
- VSZWPYCFIRKVQL-UHFFFAOYSA-N selanylidenegallium;selenium Chemical compound [Se].[Se]=[Ga].[Se]=[Ga] VSZWPYCFIRKVQL-UHFFFAOYSA-N 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Sustainable Development (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Electromagnetism (AREA)
- Plant Pathology (AREA)
- Dispersion Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Description
関連出願の相互参照
本願は、2019年7月9日に出願された国際特許出願PCT/US2019/041055号から35U.S.C.§365(c)の下で優先権を主張し、その全内容は本明細書で参照により援用される。
[背景技術]
背景説明は、本明細書に提示される方法及び技術を理解する場合に有用であるかもしれない情報を含む。本明細書に提供される情報のいずれかが先行技術であるか又は本明細書に提示される主題に関連すること又は明示的に若しくは暗示的に参照される任意の刊行物が先行技術であることは承認ではない。
[先行技術文献]
[特許文献]
[特許文献1]米国特許出願公開第2017/0037357号明細書
[非特許文献]
[非特許文献1]Leuk Res.(2009)33:1255-9
[非特許文献2]Cytotherapy(2008)10:265-74
[非特許文献3]Selmeczi,D.et al.,“Efficient large volume electroporation of dendritic
cells through micrometer scale manipulation of flow in a disposable polymer chip,”Biomed Microdevices,13:383-392(2011)
[非特許文献4]Moffett,et al.,Nature Communications(2017)8:389
[発明の概要]
[発明が解決しようとする課題]
たとえ様々なトランスフェクションシステム及び方法が哺乳動物細胞用に存在するとはいえ、かかる技術は1つ以上の不利益を被る。したがって、特にハイスループットな大規模製造プロセス向けに、改善されたエレクトロポレーションシステム及び方法を提供することが依然として求められている。
[課題を解決するための手段]
本明細書に提示される技術は、細胞、例えば哺乳動物細胞及び非哺乳動物細胞のエレクトロポレーションのための、例えば大規模な連続製造プロセス向けの様々なデバイス、システム、及び方法を対象とする。特に、第1出力からオフセット距離だけ隔てられた第1入力を含むエレクトロポレーション装置を用いる、細胞のエレクトロポレーションのためのシステム及び方法は、高い効率及び生存率を提供し得る。
[図面の簡単な説明]
[図1A-1B]平行プレート電極(図1A中に示される通り)及び入力と出力との間にオフセットを有しないマイクロメッシュ電極(図1B中に示される通り)を含む通常のエレクトロポレーション装置を示す。
[発明を実施するための形態]
細胞、例えば哺乳動物細胞(例えば、NK細胞、EC-7細胞、T細胞など)及び非哺乳動物細胞のエレクトロポレーションのためのシステム及び方法が、高い効率及び生存率を提供する対応するエレクトロポレーションプロトコルとともに提供される。いくつかの態様では、エレクトロポレーションプロトコルは、複数の電気パルス、段階的な流体フロー、低い伝導率及び低い容積モル浸透圧濃度のエレクトロポレーション緩衝液、比較的中程度の容量、並びに/又は比較的中程度の時定数を細胞に施すことを含む。
細胞にカーゴをエレクトロポレートする方法が、例えば上記のようなエレクトロポレーション装置とともに本明細書に提供される。この方法は、細胞をカーゴとともにエレクトロポレーションチャンバーに流すことを含み得る。エレクトロポレーションチャンバーは、第1電極(例えば固体電極)、第2電極(例えば固体電極)、及び第1電極と第2電極との間のそこで規定された経路を有する流体チャネル領域(すべてが本明細書に記載の通り)を含む。該装置はまた、本明細書に記載のように細胞及びカーゴのエレクトロポレーションチャンバーへの通過を可能にする第1入力と、本明細書に記載のようにエレクトロポレーションチャンバーからのエレクトロポレートされた細胞の通過を可能にする第1出力とを含む。いくつかの実施形態では、第1入力と第1出力は、オフセット距離だけ隔てられ得る。細胞は、エレクトロポレーション培地に懸濁され得る。第1電極は、本明細書に記載のように第1材料によって囲まれ得、第2電極は、本明細書に記載のように第2材料によって囲まれ得、それらは同じであっても又は異なってもよい。第1材料及び第2材料はまた、本明細書に記載のように第1外部入力と、本明細書に記載のように第1外部出力とを含んでもよい。
[実施例]
〔実施例1.haNK細胞のトランスフェクション〕
いくつかの態様では、haNK細胞のエレクトロポレーションのための条件を下の表2に示す。
EC7細胞のエレクトロポレーションにおける典型的条件を下の表3に示す。
他の態様では、種々の異なる細胞型をトランスフェクトするため、本明細書に提供される方法及びシステムを使用してもよい。例えば、本明細書に提供される方法及びシステムにより、最大108個又はそれ以上の細胞をトランスフェクトすることができる。EC7細胞、haNK細胞、CHO細胞、及びT細胞をトランスフェクトするため、本明細書に提供される方法及びシステムを使用してもよい。例えば、0.6ml/分の流速及び4×107個の細胞/mlの細胞濃度を用いてEC7細胞をトランスフェクトするため、本明細書に提示される方法及び技術を使用してもよい。別の例では、0.36ml/分の流速及び3×107個の細胞/mlの細胞濃度を用いてhaNK細胞をトランスフェクトするため、本明細書に提示される方法及び技術を使用してもよい。さらに別の例では、0.45ml/分の流速及び2.5×107個の細胞/mlの細胞濃度を用いてCHO細胞をトランスフェクトするため、本明細書に提供される方法及び技術を使用してもよい。T細胞の場合、0.44ml/分の流速及び約2×107個の細胞/mlの細胞濃度でT細胞をトランスフェクトするため、本明細書に提示される方法及び技術を使用してもよい。これらの条件は、最適な条件を達成するため、さらに変化させてもよい。
他の態様では、ポリ(β-アミノエステル)に付着されたmRNAを初代T細胞にエレクトロポレートするため、本明細書に提示される方法及びシステムを使用している。特定のポリ(β-アミノエステル)ポリマーは、有効なRNAトランスフェクション剤として作用することが示されている。
脂肪由来間葉系幹細胞(AD-MSC)を、約1×105百万個/ミリリットルの密度で剥離し、収集した。細胞をPBS及びエレクトロポレーション緩衝液で洗浄し、330万個の細胞/ミリリットルの密度でエレクトロポレーション緩衝液に懸濁した。各条件では、0.1ミリリットルの最終細胞密度での30μgのDNAをエレクトロポレートした。エレクトロポレーション条件は次の通りである:パルス幅=100us、パルス期間=340ms、電界強度は下の表4に示すように0.9から1.6kV/cmにかけて変化する。
図2Aに表す装置と類似する装置内で、下の表5中に示すエレクトロポレーションパラメータを用いて、EC-7細胞、CHO-S細胞、初代CD4/CD8T細胞、haNK細胞、初代NK細胞、活性化NK細胞、樹状細胞、AD-MSC細胞をエレクトロポレートした。
[符号の説明]
100 細胞
105 チャンバー
110 第1入力機構
112 第2入力機構
115 ポスト
120 第1出力機構
122 第2出力機構
130 偏向点
150 天井
155 上位領域
160 床
165 下位領域
200 IOCOエレクトロポレーション装置
210 第1入力
220 エレクトロポレーションチャンバー
230 第1出力
240(1) 下位マイクロメッシュ電極
240(2) 上位マイクロメッシュ電極
310 外部プレート
310-330 :エレクトロポレーション装置
330(1) 上位メッシュ
330(2) 下位メッシュ
335 曲線状経路
350 シリンジ
360 エレクトロポレーターパルサー
380 入口
390 出口
410 カートリッジ
440(1) 第1電極
440(2) 第2電極
510 サンプルチューブ
520 生成手段
530 エレクトロポレーション装置
540 コントローラ
550 収集管
560 プライミング緩衝液チューブ
570 弁
575 弁
577 緩衝液選別チューブ
580 第1のマイクロ流体デバイス
585 第2のマイクロ流体デバイス
600 エレクトロポレーション装置
620 入口
630 出口
640 電極
700a エレクトロポレーション装置
700b エレクトロポレーション装置
706 上位表面
710 第1入力
711 下位表面
715(1) 第1材料
715(2) 第2材料
720 エレクトロポレーションチャンバー
725 流体チャネル領域
730 第1出力
735 経路
740(1) 第1電極
740(2) 第2電極
741(1) 第1電極
741(2) 第2電極
745 固体金属プレート
750 第1外部入力
760 第1外部出力
800 モジュラーシステム
805 第1モジュール
807 第1容器
809 エアフィルター装置
810 チューブ
815 第2モジュール
820 エレクトロポレーション装置
825 第3モジュール
830 第2容器
850 コネクター
852 装置
854 電力供給
856 電源
858 制御回路
860 エレクトロポレーション装置
862 電力変換装置
864 パルス回路
866 コントローラ
868 パルス発生器
870 フィードバック信号
872 制御信号
874 信号
876 制御信号
878a信号
878b信号
880 信号
882 信号
884 信号
886 装置
888 電力供給
890 制御回路
892 フィルター
894 ゲートドライバ
896 制御信号
Claims (3)
- エレクトロポレーション培地であって、前記エレクトロポレーション培地は、
塩化カリウム(KCl)、塩化ナトリウム(NaCl)、塩化リチウム(LiCl)、塩化カルシウム(CaCl 2 )、塩化クロム(CrCl 3 )、臭化カリウム(KBr)、臭化ナトリウム(NaBr)、塩化マグネシウム(MgCl 2 )、臭化マグネシウム(MgBr 2 )、フッ化マグネシウム(MgF 2 )、ヨウ化マグネシウム(MgI 2 )、臭化リチウム(LiBr)、ヨウ化カリウム(KI)、ヨウ化ナトリウム(NaI)、ヨウ化リチウム(LiI)、及びそれらの組み合わせからなる群から選択される1つ以上の金属ハロゲン化物塩;
リン酸一ナトリウム(NaH 2 PO 4 )、リン酸二ナトリウム(Na 2 HPO 4 )、リン酸三ナトリウム(Na 3 PO 4 )、リン酸一マグネシウム(Mg(H 2 PO 4 ) 2 )、リン酸二マグネシウム(MgHPO 4 )、リン酸三マグネシウム(Mg 3 (PO 4 ) 2 )、リン酸一カリウム(KH 2 PO 4 )、リン酸二カリウム(K 2 HPO 4 )、リン酸三カリウム(K 3 PO 4 )、リン酸一カルシウム(Ca(H 2 PO 4 ) 2 )、リン酸二カルシウム(CaHPO 4 )、リン酸三カルシウム(Ca 3 (PO 4 ) 2 )、リン酸クロム(CrPO 4 )、及びそれらの組み合わせからなる群から選択されるリン酸塩;
前記エレクトロポレーション培地中に約40mM~約200mMの濃度で存在する単糖;並びに
ヘペス、トリス(ヒドロキシメチル)、リン酸緩衝食塩水(PBS)、及びそれらの組み合わせからなる群から選択される緩衝剤;
を含む、エレクトロポレーション培地。 - 前記金属ハロゲン化物塩及び前記リン酸塩の各々が、前記エレクトロポレーション培地中に約0.1mM~約200mMの濃度で存在し、且つ前記緩衝剤が、前記エレクトロポレーション培地中に約1mM~約100mMの濃度で存在し、且つ/又は前記エレクトロポレーション培地が、1mS/m~約20mS/mの伝導度及び約50mOsm/l~約300mOsm/lの容積モル浸透圧濃度を有する、請求項1に記載のエレクトロポレーション培地。
- 前記単糖が、グルコース、フルクトース、ガラクトース、及びそれらの組み合わせからなる群から選択される、請求項1又は2に記載のエレクトロポレーション培地。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695436P | 2018-07-09 | 2018-07-09 | |
| USPCT/US2019/041055 | 2019-07-09 | ||
| PCT/US2019/041055 WO2020014264A1 (en) | 2018-07-09 | 2019-07-09 | Micro flow-through electroporation devices and methods of cell transfection |
| JP2021501021A JP7185009B2 (ja) | 2018-07-09 | 2020-07-08 | 細胞トランスフェクションのエレクトロポレーション装置及び方法 |
| PCT/US2020/041188 WO2021007315A1 (en) | 2018-07-09 | 2020-07-08 | Electroporation devices and methods of cell transfection |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021501021A Division JP7185009B2 (ja) | 2018-07-09 | 2020-07-08 | 細胞トランスフェクションのエレクトロポレーション装置及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023018085A JP2023018085A (ja) | 2023-02-07 |
| JP7638252B2 true JP7638252B2 (ja) | 2025-03-03 |
Family
ID=67441745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021501021A Active JP7185009B2 (ja) | 2018-07-09 | 2020-07-08 | 細胞トランスフェクションのエレクトロポレーション装置及び方法 |
| JP2022187279A Active JP7638252B2 (ja) | 2018-07-09 | 2022-11-24 | 細胞トランスフェクションのエレクトロポレーション装置及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021501021A Active JP7185009B2 (ja) | 2018-07-09 | 2020-07-08 | 細胞トランスフェクションのエレクトロポレーション装置及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11377652B2 (ja) |
| EP (1) | EP3818143B1 (ja) |
| JP (2) | JP7185009B2 (ja) |
| KR (1) | KR102546174B1 (ja) |
| CN (1) | CN112639112A (ja) |
| AU (2) | AU2019301062A1 (ja) |
| DE (1) | DE112019003498B4 (ja) |
| WO (2) | WO2020014264A1 (ja) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12188042B2 (en) | 2018-07-09 | 2025-01-07 | NanoCav, LLC | Electroporation devices and methods of cell transfection |
| US12527950B2 (en) | 2018-07-09 | 2026-01-20 | NanoCav, LLC | Electroporation devices and methods of cell transfection |
| WO2020014264A1 (en) * | 2018-07-09 | 2020-01-16 | NanoCav, LLC | Micro flow-through electroporation devices and methods of cell transfection |
| US11278606B2 (en) | 2019-12-13 | 2022-03-22 | Nant Holdingsip, Llc | Methods of preparing cancer treatments and methods of treating cancer |
| WO2021183687A2 (en) | 2020-03-10 | 2021-09-16 | Cellares Corporation | Systems, devices, and methods for cell processing |
| USD1016324S1 (en) | 2020-07-08 | 2024-02-27 | NanoCav, LLC | Biological cell processing chip |
| US12006507B2 (en) | 2020-07-22 | 2024-06-11 | Nantcell, Inc. | Electroporation with active compensation |
| US12076071B2 (en) | 2020-08-14 | 2024-09-03 | Kardium Inc. | Systems and methods for treating tissue with pulsed field ablation |
| JPWO2022190943A1 (ja) * | 2021-03-08 | 2022-09-15 | ||
| JPWO2022196331A1 (ja) * | 2021-03-18 | 2022-09-22 | ||
| EP4310173A1 (en) * | 2021-04-22 | 2024-01-24 | FUJIFILM Corporation | Electric punching device, introduction method of bioactive material, producing method of tissue-derived biomaterial, and tissue-derived biomaterial |
| CN117715929A (zh) | 2021-07-29 | 2024-03-15 | 南特细胞公司 | 用于预防和治疗病毒感染和癌症的经修饰的t细胞受体 |
| CN113832033A (zh) * | 2021-09-10 | 2021-12-24 | 北京大学 | 细胞高活性分选及改造的原位电穿孔芯片、装置及方法 |
| KR20240093662A (ko) * | 2021-10-28 | 2024-06-24 | 나노카브, 엘엘씨 | 전기 천공 디바이스 및 세포 형질 감염 방법 |
| CN117660176A (zh) * | 2022-08-25 | 2024-03-08 | 苏州壹达生物科技有限公司 | 一种流式电穿孔组件 |
| KR20240048769A (ko) * | 2022-10-07 | 2024-04-16 | 주식회사 펨토바이오메드 | 형질전환 카트리지, 형질전환 장치, 이를 포함하는 형질전환 시스템 및 이를 이용하는 형질전환 방법 |
| CN115895876B (zh) * | 2022-11-30 | 2024-04-02 | 重庆大学 | 一种基于双侧流场配对结构阵列的细胞电融合芯片装置及制备方法 |
| US12180453B2 (en) | 2023-03-21 | 2024-12-31 | Cellares Corporation | Systems, devices, and methods for electroporation within a cell processing system |
| WO2024204415A1 (ja) * | 2023-03-27 | 2024-10-03 | 富士フイルム株式会社 | ウイルス産生方法 |
| US12399193B2 (en) | 2023-05-05 | 2025-08-26 | Cellares Corporation | Systems, devices, and methods for combined cell processes |
| WO2025007051A2 (en) | 2023-06-30 | 2025-01-02 | Cellares Corporation | Systems, devices, and methods for fluid transfer within an automated cell processing system |
| WO2025041064A2 (en) | 2023-08-21 | 2025-02-27 | Cellares Corporation | Systems, devices, and methods for automatic cell sorting |
| US12305156B2 (en) | 2023-08-21 | 2025-05-20 | Cellares Corporation | Systems, devices, and methods for fluid control in a cell processing system |
| US12497587B2 (en) | 2023-08-21 | 2025-12-16 | Cellares Corporation | Bioreactors and methods of their use in automatic cell processing systems |
| US12492368B2 (en) | 2024-03-11 | 2025-12-09 | Cellares Corporation | Monitoring air pressure within a cell processing system |
| WO2025202944A2 (en) | 2024-03-27 | 2025-10-02 | Cellares Corporation | Liquid level and flow rate detection within a cell processing system |
| USD1109621S1 (en) | 2024-04-15 | 2026-01-20 | Cellares Corporation | Analytical platform for biological material testing |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007532093A (ja) | 2003-05-20 | 2007-11-15 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク | エングレイルド転写因子の活性を調節するペプチド |
| JP2010525817A (ja) | 2007-04-30 | 2010-07-29 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | 高効率エレクトロポレーションバッファー |
| WO2011089953A1 (ja) | 2010-01-22 | 2011-07-28 | ネッパジーン株式会社 | エレクトロポレーション法による外来遺伝子導入法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR870008027A (ko) | 1986-02-28 | 1987-09-23 | 스튜어트 알. 수터 | 원세포의 불멸화 |
| US6074605A (en) | 1995-03-10 | 2000-06-13 | Entremed, Inc. | Flow electroporation chamber and method |
| US6395484B1 (en) * | 1997-07-23 | 2002-05-28 | Roche Diagnostics Gmbh | Identification of human cell lines for the production of human proteins by endogenous gene activation |
| AU2002326717A1 (en) | 2001-08-22 | 2003-03-10 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
| US6969604B1 (en) * | 2003-06-20 | 2005-11-29 | Yakovenko Sergey A | Electroporation chamber |
| US20050118705A1 (en) * | 2003-11-07 | 2005-06-02 | Rabbitt Richard D. | Electrical detectors for microanalysis |
| WO2006112870A1 (en) | 2005-04-19 | 2006-10-26 | Excellin Life Sciences, Inc. | Device and method for controlled electroporation and molecular delivery in cells and tissue |
| WO2009029519A2 (en) * | 2007-08-24 | 2009-03-05 | David Mark Evans | Multiplexed electroporation apparatus |
| EP2459696B1 (en) * | 2009-08-02 | 2017-11-08 | Qvella Corporation | Cell concentration, capture and lysis devices and methods of use thereof |
| WO2011050009A1 (en) * | 2009-10-19 | 2011-04-28 | Rational Biotechnology Inc. | Method, device and apparatus for inducing self-adjusting cell electroporation |
| CN101857836B (zh) * | 2009-11-10 | 2013-06-12 | 昆山文曲生物微系统有限公司 | 一种流式电穿孔装置及系统 |
| CN101928666B (zh) | 2010-07-30 | 2013-04-03 | 北京大学 | 一种流式电穿孔装置及系统 |
| CA2842720C (en) * | 2011-07-25 | 2023-10-10 | Qvella Corporation | Methods and devices for electrical sample preparation |
| CN103451097B (zh) | 2013-08-19 | 2015-05-27 | 西安交通大学 | 一种提高骨髓移植成功率的体外细胞融合系统及方法 |
| CN106232801A (zh) | 2014-04-28 | 2016-12-14 | 维瓦生物细胞股份公司 | 自动化细胞培养和收获装置 |
| CN106995783B (zh) | 2016-01-22 | 2019-11-19 | 上海交通大学 | 细胞电转染装置及其应用 |
| US11225638B2 (en) | 2016-04-04 | 2022-01-18 | CyteQuest, Inc. | System, device and method for electroporation of cells |
| US20190136224A1 (en) | 2016-05-31 | 2019-05-09 | Massachusetts Institute Of Technology | Hydrodynamically Controlled Electric Fields for High Throughput Transformation & High Throughput Parallel Transformation Platform |
| WO2018119296A1 (en) * | 2016-12-22 | 2018-06-28 | The Charles Stark Draper Laboratory, Inc. | System and method of using a microfluidic electroporation device for cell treatment |
| CN208250332U (zh) | 2017-10-19 | 2018-12-18 | 苏州壹达生物科技有限公司 | 一种流式电穿孔装置 |
| WO2019084000A1 (en) * | 2017-10-23 | 2019-05-02 | The Charles Stark Draper Laboratory, Inc. | METHOD AND APPARATUS FOR ELECTROPORTING ACOUSTICALLY ALIGNED CELLS |
| US12527950B2 (en) | 2018-07-09 | 2026-01-20 | NanoCav, LLC | Electroporation devices and methods of cell transfection |
| WO2020014264A1 (en) | 2018-07-09 | 2020-01-16 | NanoCav, LLC | Micro flow-through electroporation devices and methods of cell transfection |
| US12188042B2 (en) | 2018-07-09 | 2025-01-07 | NanoCav, LLC | Electroporation devices and methods of cell transfection |
| KR102124957B1 (ko) * | 2018-07-27 | 2020-06-22 | 엘지전자 주식회사 | 전기천공 장치 |
| US11278606B2 (en) | 2019-12-13 | 2022-03-22 | Nant Holdingsip, Llc | Methods of preparing cancer treatments and methods of treating cancer |
-
2019
- 2019-07-09 WO PCT/US2019/041055 patent/WO2020014264A1/en not_active Ceased
- 2019-07-09 DE DE112019003498.7T patent/DE112019003498B4/de active Active
- 2019-07-09 US US16/506,190 patent/US11377652B2/en active Active
- 2019-07-09 AU AU2019301062A patent/AU2019301062A1/en active Pending
-
2020
- 2020-07-08 JP JP2021501021A patent/JP7185009B2/ja active Active
- 2020-07-08 AU AU2020311908A patent/AU2020311908B2/en active Active
- 2020-07-08 CN CN202080003926.XA patent/CN112639112A/zh active Pending
- 2020-07-08 WO PCT/US2020/041188 patent/WO2021007315A1/en not_active Ceased
- 2020-07-08 KR KR1020217003710A patent/KR102546174B1/ko active Active
- 2020-07-08 EP EP20746505.5A patent/EP3818143B1/en active Active
-
2021
- 2021-07-20 US US17/380,799 patent/US12173279B2/en active Active
-
2022
- 2022-11-24 JP JP2022187279A patent/JP7638252B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007532093A (ja) | 2003-05-20 | 2007-11-15 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク | エングレイルド転写因子の活性を調節するペプチド |
| JP2010525817A (ja) | 2007-04-30 | 2010-07-29 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | 高効率エレクトロポレーションバッファー |
| WO2011089953A1 (ja) | 2010-01-22 | 2011-07-28 | ネッパジーン株式会社 | エレクトロポレーション法による外来遺伝子導入法 |
Non-Patent Citations (1)
| Title |
|---|
| TERUEL, M. N. et al.,Biophysical Journal,1997年,Vol. 73,P. 1785-1796 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3818143B1 (en) | 2024-02-28 |
| AU2019301062A1 (en) | 2021-02-04 |
| JP2023018085A (ja) | 2023-02-07 |
| WO2021007315A1 (en) | 2021-01-14 |
| JP2021535738A (ja) | 2021-12-23 |
| US20200017847A1 (en) | 2020-01-16 |
| US11377652B2 (en) | 2022-07-05 |
| JP7185009B2 (ja) | 2022-12-06 |
| DE112019003498B4 (de) | 2025-02-06 |
| AU2020311908A1 (en) | 2021-02-11 |
| US20210348155A1 (en) | 2021-11-11 |
| US12173279B2 (en) | 2024-12-24 |
| KR102546174B1 (ko) | 2023-06-20 |
| AU2020311908B2 (en) | 2023-02-23 |
| DE112019003498T5 (de) | 2021-04-08 |
| WO2020014264A1 (en) | 2020-01-16 |
| CN112639112A (zh) | 2021-04-09 |
| KR20210028687A (ko) | 2021-03-12 |
| EP3818143A1 (en) | 2021-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7638252B2 (ja) | 細胞トランスフェクションのエレクトロポレーション装置及び方法 | |
| US12527950B2 (en) | Electroporation devices and methods of cell transfection | |
| US12188042B2 (en) | Electroporation devices and methods of cell transfection | |
| US10731120B2 (en) | Flow electroporation device | |
| JP2016526923A (ja) | マイクロ流体ボルテックス支援電気穿孔システム及び方法 | |
| WO2009121555A2 (en) | Microfluidic system and method for assembling and for subsequently cultivating, and subsequent analysis of complex cell arrangements | |
| US20230109873A1 (en) | Devices, methods, and systems for electroporation using controlled parameters | |
| US11278606B2 (en) | Methods of preparing cancer treatments and methods of treating cancer | |
| US20230114435A1 (en) | Devices and methods for increasing throughput of flow-based electroporation systems | |
| Hu et al. | Automating CAR‐T transfection with micro and nano‐technologies | |
| JP7817391B2 (ja) | 細胞トランスフェクションのエレクトロポレーションデバイス及び方法 | |
| Li et al. | Current Advances and Future Prospects of Bulk and Microfluidic‐Enabled Electroporation Systems | |
| Dong et al. | Advanced microfluidic devices for cell electroporation and manipulation | |
| KR102737103B1 (ko) | 전기천공장치 | |
| Li et al. | Efficient and high-throughput electroporation chips | |
| Collini et al. | Functionalized microelectrodes arrays with integrated microfluidic channels for single-site multiple |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230529 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241024 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250218 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7638252 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |